Executive Summary
Emcure Pharmaceuticals Ltd reported Q3FY26 revenues of ₹2,363 crore, up 20.38% YoY, with consolidated net profit surging 48.08% to ₹231 crore despite ₹38 crore one-time labour code expenses. International sales exceeded 50% revenue mix with 24.5% growth, complemented by strong domestic chronic therapy performance.
Revenue & Growth
Revenues expanded to ₹2,363 crore from ₹1,963 crore YoY, driven by 24.5% international growth (₹1,338 crore) across Europe (+29.6%), Rest of World (+30.7%), and Canada (+12.8%). Domestic sales rose 15.4% to ₹1,025 crore led by cardio-diabetic therapies and Poviztra semaglutide launch.
Profitability & Margins
Consolidated net profit jumped 48% YoY to ₹231 crore from ₹156 crore, with EBITDA up 27.2% to ₹460 crore at 19.5% margins (+103 bps YoY). Basic EPS increased 49.94% to ₹12.16 from ₹8.11 despite exceptional labour code provisions.
Balance-Sheet Highlights
The dataset lacks detailed balance sheet items such as assets, liabilities, equity, net debt, or current ratio for Q3FY26.
Cash Flow / Liquidity
Operating cash flow, free cash flow, and liquidity metrics are not specified in the Q3FY26 dataset.
Key Ratios / Metrics
International business now constitutes 57% revenue mix; Europe benefited from Manx acquisition and Amphotericin B launches. Domestic weight management entry via Novo Nordisk partnership positions Emcure for obesity segment growth amid patent expiry dynamics.